Back to results

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

Primary Purpose

Breast Cancer

Status

Terminated

Phase

Phase 3

Locations

United States

Study Type

Interventional

Intervention

Fulvestrant

Anastrozole

Everolimus

Placebo - Anastrozole

Placebo - Everolimus

About this trial

This is an interventional treatment trial for Breast Cancer focused on measuring Metastatic breast cancer, Invasive breast carcinoma, estrogen receptor-positive breast cancer, HER2-negative breast cancer, Stage IV breast cancer, progesterone receptor-positive breast cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Patients must have a histologically confirmed diagnosis of invasive breast carcinoma with positive estrogen and/or progesterone receptor status, and negative human epidermal growth factor receptor (HER-2), for whom endocrine therapy is planned.
The HER-2 test result is negative (and should be reported as such), if a single test (or all tests)performed in a tumor specimen show:
- Immunohistochemistries (IHC) 1+ negative or IHC 0 negative or
- in situ hybridization (ISH) negative using a single probe ISH or dual probe ISH.
Estrogen receptor (ER) and progesterone receptor (PgR) positivity must be assessed according to American Society of Clinial Oncology (ASCO)/College of American Physicians (CAP) guidelines as either ER or PR ≥ 1% positive nuclear staining. If HER2 IHC is 2+, an evaluation for gene amplification must be performed and the gene must not be amplified. Gene amplification evaluation is not required if evaluation by IHC is 0 or 1+ by institutional standards.
Patients must be post-menopausal women with a confirmed diagnosis of metastatic breast cancer (M1). Pathologic confirmation of histology is preferable. In the case of bone metastases only, biopsy-proven metastatic disease of solitary site, or multiple sites of involvement are required. Post-menopausal is defined by one of the following criteria as per National Comprehensive Cancer Network (NCCN) guidelines Version 3. 2013:
- Prior bilateral oophorectomy and/or hysterectomy
- Patients ≥ 60 years of age
- Patients < 60 years of age and amenorrheic for ≥ 12 months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression and follicle-stimulating hormone (FSH) and estradiol in the post-menopausal range
- Patients < 60 years of age taking tamoxifen or toremifene must have FSH and plasma estradiol levels within post-menopausal ranges
Patients must have measurable or evaluable disease. Patients must have a chest and abdominal computerized tomography (CT) and bone scan within 28 days prior to registration. All scans needed for assessment of measurable disease must be performed within 28 days prior to registration. Evaluable disease must be assessed within 28 days prior to registration
Patients with a history of prior chemotherapy or hormone therapy or immunotherapy for recurrent or metastatic disease are NOT eligible. Prior adjuvant or neoadjuvant chemotherapy if completed more than 12 months prior to registration is acceptable. Any number of prior hormonal therapy regimens for the adjuvant setting but not for metastatic or recurrent disease is allowed; prior adjuvant or neoadjuvant treatment with an aromatase inhibitor (e.g. anastrozole, letrozole, exemestane) is allowed, if completed more than 12 months prior to randomization.
Patients who have taken luteinizing hormone-releasing hormone (LHRH) analogue as adjuvant therapy are eligible provided they have a) discontinued such therapy at least 12 months prior to registration AND b) have not resumed their menstrual periods.
Patients must not have had prior exposure to fulvestrant or mTOR inhibitors (e.g., rapamycin, everolimus, temsirolimus, deforolimus). Concurrent bisphosphonate therapy is allowed. Patients must not have prior treatment with any investigational drug within 28 days prior to registration and must not be planning to receive any other investigational drug for the duration of the study.
Patients must have an International Normalized Ratio (INR) ≤ 1.6 within 28 days prior to registration.
Patients must have adequate bone marrow function, as defined by Absolute Neutrophil Count (ANC) of ≥ 1,500/mL, hemoglobin ≥ 9 g/dL and a peripheral platelet count ≥ 100,000/ mL, all within 28 days prior to registration.
Patients must have adequate hepatic function obtained within 28 days prior to registration and documented by all of the following:
- Bilirubin ≤ 1.5 mg/dL (or ≤ 3.0 mg/dL if due to Gilbert's Syndrome)
- alanine aminotransferase (ALT) (SGPT) and aspartate aminotransferase (AST) (SGOT) ≤ 2.5 x Institutional Upper Limit of Normal (IULN), or ≤ 5 x IULN if hepatic metastases are present.
Patients must have adequate renal function with serum creatinine level ≤ IULN within 28 days prior to registration.
Patients must have a fasting cholesterol ≤ 300 mg/dL and triglycerides ≤ 2.5 x IULN obtained within 28 days prior to registration. Patients may be on lipid lowering agents to reach these values.
Patients must have a complete history and physical examination within 28 days prior to registration.
Patients with bleeding diathesis (i.e., disseminated intravascular coagulation [DIC], clotting factor deficiency) or long-term anti-coagulant therapy (other than antiplatelet therapy) are NOT eligible.
Patients with presence of life-threatening metastatic visceral disease, defined as extensive hepatic involvement, or any degree of brain or leptomeningeal involvement (past or present), or symptomatic pulmonary lymphangitic spread are not eligible. Patients with discrete pulmonary parenchymal metastases are eligible, provided their respiratory function is not significantly compromised as a result of disease in the opinion of the investigator.
Patients must have a performance status of 0 - 2 by Zubrod criteria.
Patients must not have any Grade III/IV cardiac disease as defined by the New York Heart Association Criteria (i.e., patients with cardiac disease resulting in marked limitation of physical activity or resulting in inability to carry on any physical activity without discomfort), unstable angina pectoris, myocardial infarction within 6 months, or serious uncontrolled cardiac arrhythmia.
Patients must not have uncontrolled diabetes (defined as an Hg A1C >7% within 28 days prior to registration).
Patients must not have an organ allograft or other history of immune compromise. Patients must not be receiving chronic, systemic treatment with corticosteroids or other immunosuppressive agent. Topical or inhaled corticosteroids are allowed.
Patients known to be HIV positive may be enrolled if baseline CD4 count is > 500 cells/mm3 AND not taking anti-retroviral therapy. Patients with known chronic or active hepatitis are not eligible. Patients must not have any known uncontrolled underlying pulmonary disease.
Patients must be able to take oral medications. Patient may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).
Patients must not have received immunization with an attenuated live vaccine (e.g. intranasal influenza, MMR, oral polio, varicella, zoster, yellow fever and BCG vaccines) within seven days prior to registration nor have plans to receive such vaccination while on protocol treatment.
Patients must not have taken within 14 days prior to registration, be taking, nor plan to take while on protocol treatment, strong CYP3A4 inhibitors, and/or CYP3A4 inducers.
No other prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or other cancer for which the patient has been disease-free for 5 years.

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Experimental

Arm Label

Arm 1: fulvestrant + everolimus placebo + anastrozole placebo

Arm 2: fulvestrant + everolimus + anastrozole placebo

Arm 3: fulvestrant + everolimus + anastrozole

Arm Description

Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive an oral placebo daily for both everolimus and anastrozole. This treatment regimen will continue until disease progression or toxicity.

Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive an oral everolimus and an oral placebo for anastrozole daily. This treatment regimen will continue until disease progression or toxicity.

Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive everolimus and anastrozole by mouth daily. This treatment regimen will continue until disease progression or toxicity.

Outcomes

Primary Outcome Measures

Progression-Free Survival (Fulvestrant vs Fulvestrant + Everolimus )

From date of registration to date of first documentation of progression or death due to any cause. Participants last known to be alive are censored at date of last contact.

Progression-free Survival (Fulvestrant Versus Fulvestrant + Everolimus + Anastrozole)

From date of registration to date of first documentation of progression or death due to any cause. Participants last known to be alive without report of progression are censored at date of last contact.

Secondary Outcome Measures

Progression Free Survival (Fulvestrant + Everolimus vs Fulvestrant + Everolimus + Anastrozole)

Overall Survival

From date of registration to date of death due to any cause. Participants last known to be alive without report of progression are censored at date of last contact.

Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs

Adverse Events (AEs) are reported by CTCAE Version 4.0. Only adverse events that are possibly, probably or definitely related to study drug are reported.

Response Rate

Proportion of participants who have confirmed or unconfirmed partial or complete response to therapy

Clinical Benefit Rate

Proportion of participants who have confirmed and unconfirmed partial response, complete response or stable disease.

Molecular Determinants of Response in Circulating Tumor Cells: CTC-ETI

CTC-Endocrine Therapy Index (CTC-ETI) on the CellSearch® platform. Based on enumeration of CTC/7.5 mL of whole blood, with >= 5 being elevated. (Due to limited samples collected, full analysis was not able to be performed as planned, so outcome measure reported here is number with elevated Day 1 CTC.)

Full Information

NCT ID

NCT02137837

First Posted

May 12, 2014

Last Updated

January 5, 2021

Sponsor

SWOG Cancer Research Network

Collaborators

AstraZeneca, Novartis

1. Study Identification

Unique Protocol Identification Number

NCT02137837

Brief Title

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

Official Title

Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients

Study Type

Interventional

2. Study Status

Record Verification Date

January 2021

Overall Recruitment Status

Terminated

Why Stopped

lack of accrual

Study Start Date

May 2014 (undefined)

Primary Completion Date

December 31, 2019 (Actual)

Study Completion Date

December 31, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

SWOG Cancer Research Network

Collaborators

AstraZeneca, Novartis

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This randomized Phase III trial studies how well the combination of fulvestrant and everolimus together or the combination of anastrozole, fulvestrant and everolimus together, improve progression-free survival (PFS) versus fulvestrant alone.

Detailed Description

OBJECTIVES: Primary To test the benefit of interfering with the function of the estrogen receptor (ER) and providing downstream target inhibition (PI3K/AKT/mTOR) with a combination of optimal dose fulvestrant and everolimus (Arm 2) to improve progression-free survival compared to the optimal dose fulvestrant alone (Arm 1). To test the benefit of adding the non-steroidal aromatase inhibitor anastrozole to optimal dose fulvestrant and everolimus (Arm 3) in order to improve progression free survival over optimal dose fulvestrant (Arm 1). Secondary To compare progression-free survival among those receiving fulvestrant + everolimus + anastrozole (Arm 3) versus fulvestrant + everolimus (Arm 2). To compare overall survival among the treatment arms in post-menopausal patients with hormone-receptor positive (HR+) Stage IV breast cancer. To assess and compare toxicities, feasibility and compliance among the study regimens. To compare response rates and clinical benefit rates among the study regimens. To test molecular determinants of response to endocrine therapy and everolimus in circulating tumor cells: CTC-Endocrine Therapy Index (CTC ETI) on the CellSearch® platform. CTC-Next Generation Sequencing Analysis (CTC-NGS) of single cells captured on the HD-CTC® platform. OUTLINE: This is a multicenter study. Patients will be stratified according to the following factors: Measurable versus evaluable non-measurable disease Prior adjuvant hormonal therapy completed more than 5 years ago vs. prior adjuvant hormonal therapy completed 1-5 years ago vs. de novo presentation of metastatic disease or no prior adjuvant hormonal therapy. ARMS: Arm 1: fulvestrant + placebo (everolimus) + placebo (anastrozole) Arm 2: fulvestrant + everolimus + placebo (anastrozole) Arm 3: fulvestrant + everolimus + anastrozole Blood and tissue samples are collected for correlative science studies. After completion of study treatment, patients are followed up every 6 months for 2 years and then yearly thereafter for 5 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Breast Cancer

Keywords

Metastatic breast cancer, Invasive breast carcinoma, estrogen receptor-positive breast cancer, HER2-negative breast cancer, Stage IV breast cancer, progesterone receptor-positive breast cancer

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigator

Allocation

Randomized

Enrollment

37 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Arm 1: fulvestrant + everolimus placebo + anastrozole placebo

Arm Type

Placebo Comparator

Arm Description

Arm Title

Arm 2: fulvestrant + everolimus + anastrozole placebo

Arm Type

Experimental

Arm Description

Arm Title

Arm 3: fulvestrant + everolimus + anastrozole

Arm Type

Experimental

Arm Description

Intervention Type

Drug

Intervention Name(s)

Fulvestrant

Other Intervention Name(s)

Faslodex, NSC-719276

Intervention Type

Drug

Intervention Name(s)

Anastrozole

Other Intervention Name(s)

Arimidex, NSC-719344

Intervention Type

Drug

Intervention Name(s)

Everolimus

Other Intervention Name(s)

Afinitor, Zortress, NSC-733504

Intervention Type

Drug

Intervention Name(s)

Placebo - Anastrozole

Intervention Type

Drug

Intervention Name(s)

Placebo - Everolimus

Primary Outcome Measure Information:

Title

Progression-Free Survival (Fulvestrant vs Fulvestrant + Everolimus )

Description

From date of registration to date of first documentation of progression or death due to any cause. Participants last known to be alive are censored at date of last contact.

Time Frame

up to 5 years

Title

Progression-free Survival (Fulvestrant Versus Fulvestrant + Everolimus + Anastrozole)

Description

Time Frame

up to 5 years

Secondary Outcome Measure Information:

Title

Progression Free Survival (Fulvestrant + Everolimus vs Fulvestrant + Everolimus + Anastrozole)

Description

Time Frame

up to 5 years

Title

Overall Survival

Description

From date of registration to date of death due to any cause. Participants last known to be alive without report of progression are censored at date of last contact.

Time Frame

up to 5 years

Title

Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs

Description

Adverse Events (AEs) are reported by CTCAE Version 4.0. Only adverse events that are possibly, probably or definitely related to study drug are reported.

Time Frame

Duration of treatment and follow up until death or 5 years post registration

Title

Response Rate

Description

Proportion of participants who have confirmed or unconfirmed partial or complete response to therapy

Time Frame

assessed every 12 weeks, up to 5 years

Title

Clinical Benefit Rate

Description

Proportion of participants who have confirmed and unconfirmed partial response, complete response or stable disease.

Time Frame

assessed every 12 weeks, up to 5 years

Title

Molecular Determinants of Response in Circulating Tumor Cells: CTC-ETI

Description

Time Frame

Day 1, Day 29, time of progression (Day 29 to be collected only if Day 1 CTC was elevated.)

10. Eligibility

Sex

Female

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Patients must have a histologically confirmed diagnosis of invasive breast carcinoma with positive estrogen and/or progesterone receptor status, and negative human epidermal growth factor receptor (HER-2), for whom endocrine therapy is planned. The HER-2 test result is negative (and should be reported as such), if a single test (or all tests)performed in a tumor specimen show: Immunohistochemistries (IHC) 1+ negative or IHC 0 negative or in situ hybridization (ISH) negative using a single probe ISH or dual probe ISH. Estrogen receptor (ER) and progesterone receptor (PgR) positivity must be assessed according to American Society of Clinial Oncology (ASCO)/College of American Physicians (CAP) guidelines as either ER or PR ≥ 1% positive nuclear staining. If HER2 IHC is 2+, an evaluation for gene amplification must be performed and the gene must not be amplified. Gene amplification evaluation is not required if evaluation by IHC is 0 or 1+ by institutional standards. Patients must be post-menopausal women with a confirmed diagnosis of metastatic breast cancer (M1). Pathologic confirmation of histology is preferable. In the case of bone metastases only, biopsy-proven metastatic disease of solitary site, or multiple sites of involvement are required. Post-menopausal is defined by one of the following criteria as per National Comprehensive Cancer Network (NCCN) guidelines Version 3. 2013: Prior bilateral oophorectomy and/or hysterectomy Patients ≥ 60 years of age Patients < 60 years of age and amenorrheic for ≥ 12 months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression and follicle-stimulating hormone (FSH) and estradiol in the post-menopausal range Patients < 60 years of age taking tamoxifen or toremifene must have FSH and plasma estradiol levels within post-menopausal ranges Patients must have measurable or evaluable disease. Patients must have a chest and abdominal computerized tomography (CT) and bone scan within 28 days prior to registration. All scans needed for assessment of measurable disease must be performed within 28 days prior to registration. Evaluable disease must be assessed within 28 days prior to registration Patients with a history of prior chemotherapy or hormone therapy or immunotherapy for recurrent or metastatic disease are NOT eligible. Prior adjuvant or neoadjuvant chemotherapy if completed more than 12 months prior to registration is acceptable. Any number of prior hormonal therapy regimens for the adjuvant setting but not for metastatic or recurrent disease is allowed; prior adjuvant or neoadjuvant treatment with an aromatase inhibitor (e.g. anastrozole, letrozole, exemestane) is allowed, if completed more than 12 months prior to randomization. Patients who have taken luteinizing hormone-releasing hormone (LHRH) analogue as adjuvant therapy are eligible provided they have a) discontinued such therapy at least 12 months prior to registration AND b) have not resumed their menstrual periods. Patients must not have had prior exposure to fulvestrant or mTOR inhibitors (e.g., rapamycin, everolimus, temsirolimus, deforolimus). Concurrent bisphosphonate therapy is allowed. Patients must not have prior treatment with any investigational drug within 28 days prior to registration and must not be planning to receive any other investigational drug for the duration of the study. Patients must have an International Normalized Ratio (INR) ≤ 1.6 within 28 days prior to registration. Patients must have adequate bone marrow function, as defined by Absolute Neutrophil Count (ANC) of ≥ 1,500/mL, hemoglobin ≥ 9 g/dL and a peripheral platelet count ≥ 100,000/ mL, all within 28 days prior to registration. Patients must have adequate hepatic function obtained within 28 days prior to registration and documented by all of the following: Bilirubin ≤ 1.5 mg/dL (or ≤ 3.0 mg/dL if due to Gilbert's Syndrome) alanine aminotransferase (ALT) (SGPT) and aspartate aminotransferase (AST) (SGOT) ≤ 2.5 x Institutional Upper Limit of Normal (IULN), or ≤ 5 x IULN if hepatic metastases are present. Patients must have adequate renal function with serum creatinine level ≤ IULN within 28 days prior to registration. Patients must have a fasting cholesterol ≤ 300 mg/dL and triglycerides ≤ 2.5 x IULN obtained within 28 days prior to registration. Patients may be on lipid lowering agents to reach these values. Patients must have a complete history and physical examination within 28 days prior to registration. Patients with bleeding diathesis (i.e., disseminated intravascular coagulation [DIC], clotting factor deficiency) or long-term anti-coagulant therapy (other than antiplatelet therapy) are NOT eligible. Patients with presence of life-threatening metastatic visceral disease, defined as extensive hepatic involvement, or any degree of brain or leptomeningeal involvement (past or present), or symptomatic pulmonary lymphangitic spread are not eligible. Patients with discrete pulmonary parenchymal metastases are eligible, provided their respiratory function is not significantly compromised as a result of disease in the opinion of the investigator. Patients must have a performance status of 0 - 2 by Zubrod criteria. Patients must not have any Grade III/IV cardiac disease as defined by the New York Heart Association Criteria (i.e., patients with cardiac disease resulting in marked limitation of physical activity or resulting in inability to carry on any physical activity without discomfort), unstable angina pectoris, myocardial infarction within 6 months, or serious uncontrolled cardiac arrhythmia. Patients must not have uncontrolled diabetes (defined as an Hg A1C >7% within 28 days prior to registration). Patients must not have an organ allograft or other history of immune compromise. Patients must not be receiving chronic, systemic treatment with corticosteroids or other immunosuppressive agent. Topical or inhaled corticosteroids are allowed. Patients known to be HIV positive may be enrolled if baseline CD4 count is > 500 cells/mm3 AND not taking anti-retroviral therapy. Patients with known chronic or active hepatitis are not eligible. Patients must not have any known uncontrolled underlying pulmonary disease. Patients must be able to take oral medications. Patient may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection). Patients must not have received immunization with an attenuated live vaccine (e.g. intranasal influenza, MMR, oral polio, varicella, zoster, yellow fever and BCG vaccines) within seven days prior to registration nor have plans to receive such vaccination while on protocol treatment. Patients must not have taken within 14 days prior to registration, be taking, nor plan to take while on protocol treatment, strong CYP3A4 inhibitors, and/or CYP3A4 inducers. No other prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or other cancer for which the patient has been disease-free for 5 years.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Halle Moore, M.D.

Organizational Affiliation

The Cleveland Clinic

Official's Role

Study Chair

Facility Information:

Facility Name

Alaska Breast Care and Surgery LLC

City

Anchorage

State/Province

Alaska

ZIP/Postal Code

99508

Country

United States

Facility Name

Alaska Women's Cancer Care

City

Anchorage

State/Province

Alaska

ZIP/Postal Code

99508

Country

United States

Facility Name

Anchorage Oncology Centre

City

Anchorage

State/Province

Alaska

ZIP/Postal Code

99508

Country

United States

Facility Name

Katmai Oncology Group

City

Anchorage

State/Province

Alaska

ZIP/Postal Code

99508

Country

United States

Facility Name

Providence Alaska Medical Center

City

Anchorage

State/Province

Alaska

ZIP/Postal Code

99508

Country

United States

Facility Name

Virginia G. Piper Cancer Center

City

Scottsdale

State/Province

Arizona

ZIP/Postal Code

85258

Country

United States

Facility Name

University of Arizona Cancer Center - Orange Grove

City

Tucson

State/Province

Arizona

ZIP/Postal Code

85704

Country

United States

Facility Name

University of Arizona Cancer Center - North Campus

City

Tucson

State/Province

Arizona

ZIP/Postal Code

85719

Country

United States

Facility Name

Southern Arizona VA Health Care System

City

Tucson

State/Province

Arizona

ZIP/Postal Code

85723

Country

United States

Facility Name

University of Arizona Medical Center - Univ Campus

City

Tucson

State/Province

Arizona

ZIP/Postal Code

85724

Country

United States

Facility Name

University of Arkansas for Medical Sciences

City

Little Rock

State/Province

Arkansas

ZIP/Postal Code

72205

Country

United States

Facility Name

Providence St. Joseph Medical Ctr/Disney Family CC

City

Burbank

State/Province

California

ZIP/Postal Code

91505

Country

United States

Facility Name

City of Hope-Corona

City

Corona

State/Province

California

ZIP/Postal Code

92879

Country

United States

Facility Name

City of Hope National Medical Center

City

Duarte

State/Province

California

ZIP/Postal Code

91010

Country

United States

Facility Name

City of Hope Antelope Valley

City

Lancaster

State/Province

California

ZIP/Postal Code

93534

Country

United States

Facility Name

Bay Area Tumor Institute

City

Oakland

State/Province

California

ZIP/Postal Code

94609

Country

United States

Facility Name

Summit Medical Center

City

Oakland

State/Province

California

ZIP/Postal Code

94609

Country

United States

Facility Name

Epic Care - Oakland

City

Oakland

State/Province

California

ZIP/Postal Code

94612

Country

United States

Facility Name

City of Hope South Pasadena

City

South Pasadena

State/Province

California

ZIP/Postal Code

91030

Country

United States

Facility Name

Bridgeport Hospital

City

Bridgeport

State/Province

Connecticut

ZIP/Postal Code

06610

Country

United States

Facility Name

St. Francis Hospital and Medical Center

City

Hartford

State/Province

Connecticut

ZIP/Postal Code

06105

Country

United States

Facility Name

Yale University

City

New Haven

State/Province

Connecticut

ZIP/Postal Code

06520

Country

United States

Facility Name

Yale-New Haven Hospital North Haven Medical Center

City

North Haven

State/Province

Connecticut

ZIP/Postal Code

06473

Country

United States

Facility Name

Sacred Heart Hospital

City

Pensacola

State/Province

Florida

ZIP/Postal Code

32504

Country

United States

Facility Name

Cleveland Clinic - Weston

City

Weston

State/Province

Florida

ZIP/Postal Code

33331

Country

United States

Facility Name

South Georgia Medical Center - Pearlman Cancer Ctr

City

Valdosta

State/Province

Georgia

ZIP/Postal Code

31602

Country

United States

Facility Name

Oncare Hawaii, Inc - Pali Momi

City

'Aiea

State/Province

Hawaii

ZIP/Postal Code

96701

Country

United States

Facility Name

Pali Momi Medical Center

City

'Aiea

State/Province

Hawaii

ZIP/Postal Code

96701

Country

United States

Facility Name

Oncare Hawaii Inc-POB I

City

Honolulu

State/Province

Hawaii

ZIP/Postal Code

96813

Country

United States

Facility Name

Oncare Hawaii, Inc - POB II

City

Honolulu

State/Province

Hawaii

ZIP/Postal Code

96813

Country

United States

Facility Name

Straub Clinic and Hospital

City

Honolulu

State/Province

Hawaii

ZIP/Postal Code

96813

Country

United States

Facility Name

University of Hawaii Cancer Center

City

Honolulu

State/Province

Hawaii

ZIP/Postal Code

96813

Country

United States

Facility Name

Oncare Hawaii, Inc - Kuakini

City

Honolulu

State/Province

Hawaii

ZIP/Postal Code

96817

Country

United States

Facility Name

Oncare Hawaii, Inc - Liliha

City

Honolulu

State/Province

Hawaii

ZIP/Postal Code

96817

Country

United States

Facility Name

Kapiolani Medical Center for Women and Children

City

Honolulu

State/Province

Hawaii

ZIP/Postal Code

96826

Country

United States

Facility Name

Wilcox Memorial Hospital and Kauai Medical Clinic

City

Lihue

State/Province

Hawaii

ZIP/Postal Code

96766

Country

United States

Facility Name

St. Alphonsus Regional Medical Center

City

Boise

State/Province

Idaho

ZIP/Postal Code

83706

Country

United States

Facility Name

Kootenai Medical Center

City

Coeur d'Alene

State/Province

Idaho

ZIP/Postal Code

83814

Country

United States

Facility Name

Kootenai Cancer Center

City

Post Falls

State/Province

Idaho

ZIP/Postal Code

83854

Country

United States

Facility Name

Kootenai Cancer Clinic

City

Sandpoint

State/Province

Idaho

ZIP/Postal Code

83864

Country

United States

Facility Name

Centralia Oncology Clinic

City

Centralia

State/Province

Illinois

ZIP/Postal Code

62801

Country

United States

Facility Name

Cancer Care Specialists of Central Illinois

City

Decatur

State/Province

Illinois

ZIP/Postal Code

62526

Country

United States

Facility Name

Decatur Memorial Hospital

City

Decatur

State/Province

Illinois

ZIP/Postal Code

62526

Country

United States

Facility Name

Heartland Cancer Research NCORP

City

Decatur

State/Province

Illinois

ZIP/Postal Code

62526

Country

United States

Facility Name

Kishwaukee Community Hospital

City

DeKalb

State/Province

Illinois

ZIP/Postal Code

60115

Country

United States

Facility Name

Crossroads Cancer Center

City

Effingham

State/Province

Illinois

ZIP/Postal Code

62401

Country

United States

Facility Name

Loyola University Stritch School of Medicine

City

Maywood

State/Province

Illinois

ZIP/Postal Code

60153

Country

United States

Facility Name

Marjorie Weinberg Cancer Center

City

Melrose Park

State/Province

Illinois

ZIP/Postal Code

60160

Country

United States

Facility Name

Good Samaritan Regional Health Center

City

Mount Vernon

State/Province

Illinois

ZIP/Postal Code

62864

Country

United States

Facility Name

Central Illinois Hematology Oncology Center

City

Springfield

State/Province

Illinois

ZIP/Postal Code

62702

Country

United States

Facility Name

Springfield Clinic

City

Springfield

State/Province

Illinois

ZIP/Postal Code

62703

Country

United States

Facility Name

Memorial Medical Center

City

Springfield

State/Province

Illinois

ZIP/Postal Code

62781

Country

United States

Facility Name

Cancer Care Specialists of Illinois-Swansea

City

Swansea

State/Province

Illinois

ZIP/Postal Code

62226

Country

United States

Facility Name

Reid Hospital and Health Care Services

City

Richmond

State/Province

Indiana

ZIP/Postal Code

47374

Country

United States

Facility Name

Cancer Center of Kansas - Chanute

City

Chanute

State/Province

Kansas

ZIP/Postal Code

66720

Country

United States

Facility Name

Cancer Center of Kansas - Dodge City

City

Dodge City

State/Province

Kansas

ZIP/Postal Code

67801

Country

United States

Facility Name

Cancer Center of Kansas - El Dorado

City

El Dorado

State/Province

Kansas

ZIP/Postal Code

67042

Country

United States

Facility Name

Cancer Center of Kansas - Fort Scott

City

Fort Scott

State/Province

Kansas

ZIP/Postal Code

66701

Country

United States

Facility Name

Cancer Center of Kansas - Independence

City

Independence

State/Province

Kansas

ZIP/Postal Code

67301

Country

United States

Facility Name

Cancer Center of Kansas - Kingman

City

Kingman

State/Province

Kansas

ZIP/Postal Code

67068

Country

United States

Facility Name

Lawrence Memorial Hospital

City

Lawrence

State/Province

Kansas

ZIP/Postal Code

66044

Country

United States

Facility Name

Cancer Center of Kansas - Liberal

City

Liberal

State/Province

Kansas

ZIP/Postal Code

67901

Country

United States

Facility Name

Cancer Center of Kansas - Newton

City

Newton

State/Province

Kansas

ZIP/Postal Code

67114

Country

United States

Facility Name

Cancer Center of Kansas - Parsons

City

Parsons

State/Province

Kansas

ZIP/Postal Code

67357

Country

United States

Facility Name

Cancer Center of Kansas - Pratt

City

Pratt

State/Province

Kansas

ZIP/Postal Code

67124

Country

United States

Facility Name

Cancer Center of Kansas - Salina

City

Salina

State/Province

Kansas

ZIP/Postal Code

67401

Country

United States

Facility Name

Cancer Center of Kansas - Wellington

City

Wellington

State/Province

Kansas

ZIP/Postal Code

67152

Country

United States

Facility Name

Associates in Women's Health

City

Wichita

State/Province

Kansas

ZIP/Postal Code

67208

Country

United States

Facility Name

Cancer Center of Kansas - Medical Arts Tower

City

Wichita

State/Province

Kansas

ZIP/Postal Code

67208

Country

United States

Facility Name

Cancer Center of Kansas - Wichita

City

Wichita

State/Province

Kansas

ZIP/Postal Code

67214

Country

United States

Facility Name

Via Christi Regional Medical Center

City

Wichita

State/Province

Kansas

ZIP/Postal Code

67214

Country

United States

Facility Name

Wichita NCI Community Oncology Research Program

City

Wichita

State/Province

Kansas

ZIP/Postal Code

67214

Country

United States

Facility Name

Cancer Center of Kansas - Winfield

City

Winfield

State/Province

Kansas

ZIP/Postal Code

67156

Country

United States

Facility Name

De Soto Regional Medical Center

City

Mansfield

State/Province

Louisiana

ZIP/Postal Code

71052

Country

United States

Facility Name

University Health Conway

City

Monroe

State/Province

Louisiana

ZIP/Postal Code

71210

Country

United States

Facility Name

Highland Clinic

City

Shreveport

State/Province

Louisiana

ZIP/Postal Code

71105

Country

United States

Facility Name

Louisiana State University Health Sciences Center

City

Shreveport

State/Province

Louisiana

ZIP/Postal Code

71130

Country

United States

Facility Name

Sinai Hospital of Baltimore

City

Baltimore

State/Province

Maryland

ZIP/Postal Code

21215

Country

United States

Facility Name

Beverly Hospital

City

Beverly

State/Province

Massachusetts

ZIP/Postal Code

01915

Country

United States

Facility Name

Lahey Hospital and Medical Center

City

Burlington

State/Province

Massachusetts

ZIP/Postal Code

01805

Country

United States

Facility Name

Addison Gilbert Hospital

City

Gloucester

State/Province

Massachusetts

ZIP/Postal Code

01930

Country

United States

Facility Name

Winchester Hospital

City

Winchester

State/Province

Massachusetts

ZIP/Postal Code

01890

Country

United States

Facility Name

Michigan Cancer Research Consortium NCORP

City

Ann Arbor

State/Province

Michigan

ZIP/Postal Code

48106

Country

United States

Facility Name

St. Joseph Mercy Hospital

City

Ann Arbor

State/Province

Michigan

ZIP/Postal Code

48106

Country

United States

Facility Name

University of Michigan Medical Center

City

Ann Arbor

State/Province

Michigan

ZIP/Postal Code

48109

Country

United States

Facility Name

Oakwood Healthcare, Inc.

City

Dearborn

State/Province

Michigan

ZIP/Postal Code

48123

Country

United States

Facility Name

Wayne State University Medical Center

City

Detroit

State/Province

Michigan

ZIP/Postal Code

48202

Country

United States

Facility Name

St. John Hospital and Medical Center

City

Detroit

State/Province

Michigan

ZIP/Postal Code

48236

Country

United States

Facility Name

Genesys Hurley Cancer Institute

City

Flint

State/Province

Michigan

ZIP/Postal Code

48503

Country

United States

Facility Name

Hurley Medical Center

City

Flint

State/Province

Michigan

ZIP/Postal Code

48503

Country

United States

Facility Name

William Beaumont Hospital-Grosse Pointe

City

Grosse Pointe

State/Province

Michigan

ZIP/Postal Code

48230

Country

United States

Facility Name

Allegiance Health

City

Jackson

State/Province

Michigan

ZIP/Postal Code

49201

Country

United States

Facility Name

Sparrow Health System

City

Lansing

State/Province

Michigan

ZIP/Postal Code

48909

Country

United States

Facility Name

St. Mary Mercy Hospital

City

Livonia

State/Province

Michigan

ZIP/Postal Code

48154

Country

United States

Facility Name

MidMichigan Medical Center - Midland

City

Midland

State/Province

Michigan

ZIP/Postal Code

48670

Country

United States

Facility Name

St Joseph Mercy Hospital - Oakland

City

Pontiac

State/Province

Michigan

ZIP/Postal Code

48341

Country

United States

Facility Name

St. Joseph Mercy Port Huron

City

Port Huron

State/Province

Michigan

ZIP/Postal Code

48060

Country

United States

Facility Name

Beaumont Children's Hospital-Royal Oak

City

Royal Oak

State/Province

Michigan

ZIP/Postal Code

48073

Country

United States

Facility Name

Beaumont NCI Community Oncology Research Program

City

Royal Oak

State/Province

Michigan

ZIP/Postal Code

48073

Country

United States

Facility Name

St. Mary's Health System

City

Saginaw

State/Province

Michigan

ZIP/Postal Code

48601

Country

United States

Facility Name

Beaumont Hospital, Troy Campus

City

Troy

State/Province

Michigan

ZIP/Postal Code

48085

Country

United States

Facility Name

St. John Macomb Hospital

City

Warren

State/Province

Michigan

ZIP/Postal Code

48093

Country

United States

Facility Name

University of Mississippi Medical Center

City

Jackson

State/Province

Mississippi

ZIP/Postal Code

39216

Country

United States

Facility Name

Central Care Cancer Ctr-Carrie J. Babb Cancer Ctr

City

Bolivar

State/Province

Missouri

ZIP/Postal Code

65613

Country

United States

Facility Name

Cox Cancer Center Branson

City

Branson

State/Province

Missouri

ZIP/Postal Code

65616

Country

United States

Facility Name

St. Francis Medical Center

City

Cape Girardeau

State/Province

Missouri

ZIP/Postal Code

63701

Country

United States

Facility Name

Mercy Hospital - Joplin

City

Joplin

State/Province

Missouri

ZIP/Postal Code

64804

Country

United States

Facility Name

Mercy Clinic Care and Hematology - Rolla

City

Rolla

State/Province

Missouri

ZIP/Postal Code

65401

Country

United States

Facility Name

PCRMC Bond Clinic

City

Rolla

State/Province

Missouri

ZIP/Postal Code

65401

Country

United States

Facility Name

Phelps County Regional Medical Center

City

Rolla

State/Province

Missouri

ZIP/Postal Code

65401

Country

United States

Facility Name

St. Louis Cancer and Breast Institute-South City

City

Saint Louis

State/Province

Missouri

ZIP/Postal Code

63109

Country

United States

Facility Name

Christian Hospital

City

Saint Louis

State/Province

Missouri

ZIP/Postal Code

63136

Country

United States

Facility Name

Mercy Hospital St. Louis

City

Saint Louis

State/Province

Missouri

ZIP/Postal Code

63141

Country

United States

Facility Name

Cancer Research for the Ozarks NCORP

City

Springfield

State/Province

Missouri

ZIP/Postal Code

65804

Country

United States

Facility Name

Mercy Hospital Springfield

City

Springfield

State/Province

Missouri

ZIP/Postal Code

65804

Country

United States

Facility Name

CoxHealth South Hospital

City

Springfield

State/Province

Missouri

ZIP/Postal Code

65807

Country

United States

Facility Name

Mercy Hospital Washington

City

Washington

State/Province

Missouri

ZIP/Postal Code

63090

Country

United States

Facility Name

Montana Cancer Consortium NCORP

City

Billings

State/Province

Montana

ZIP/Postal Code

59101

Country

United States

Facility Name

Billings Clinic Cancer Center

City

Billings

State/Province

Montana

ZIP/Postal Code

59107

Country

United States

Facility Name

Bozeman Deaconess Hospital

City

Bozeman

State/Province

Montana

ZIP/Postal Code

59715

Country

United States

Facility Name

St. James Community Hosp and Cancer Treatment Center

City

Butte

State/Province

Montana

ZIP/Postal Code

59702

Country

United States

Facility Name

Benefis Healthcare West Campus

City

Great Falls

State/Province

Montana

ZIP/Postal Code

59405

Country

United States

Facility Name

St. Peter's Community Hospital

City

Helena

State/Province

Montana

ZIP/Postal Code

59601

Country

United States

Facility Name

Kalispell Regional Medical Center

City

Kalispell

State/Province

Montana

ZIP/Postal Code

59901

Country

United States

Facility Name

Community Medical Center

City

Missoula

State/Province

Montana

ZIP/Postal Code

59801

Country

United States

Facility Name

St. Patrick Hospital

City

Missoula

State/Province

Montana

ZIP/Postal Code

59806

Country

United States

Facility Name

CHI Health Good Samaritan Hospital

City

Kearney

State/Province

Nebraska

ZIP/Postal Code

68847

Country

United States

Facility Name

Southeastern Medical Oncology Center-Clinton

City

Clinton

State/Province

North Carolina

ZIP/Postal Code

28328

Country

United States

Facility Name

Southeastern Medical Oncology Center-Goldsboro

City

Goldsboro

State/Province

North Carolina

ZIP/Postal Code

27534

Country

United States

Facility Name

Wayne Memorial Hospital

City

Goldsboro

State/Province

North Carolina

ZIP/Postal Code

27534

Country

United States

Facility Name

Hendersonville Hematology and Oncology at Pardee

City

Hendersonville

State/Province

North Carolina

ZIP/Postal Code

28739

Country

United States

Facility Name

Margaret R. Pardee Memorial Hospital

City

Hendersonville

State/Province

North Carolina

ZIP/Postal Code

28791

Country

United States

Facility Name

Park Ridge Health

City

Hendersonville

State/Province

North Carolina

ZIP/Postal Code

28792

Country

United States

Facility Name

Southeastern Medical Oncology Center-Jacksonville

City

Jacksonville

State/Province

North Carolina

ZIP/Postal Code

28546

Country

United States

Facility Name

Southeastern Medical Oncology Center-Wilson

City

Wilson

State/Province

North Carolina

ZIP/Postal Code

27893

Country

United States

Facility Name

Wilson Medical Center

City

Wilson

State/Province

North Carolina

ZIP/Postal Code

27893

Country

United States

Facility Name

Cleveland Clinic Cancer Center - Beachwood

City

Beachwood

State/Province

Ohio

ZIP/Postal Code

44122

Country

United States

Facility Name

Strecker Cancer Center-Belpre

City

Belpre

State/Province

Ohio

ZIP/Postal Code

45714

Country

United States

Facility Name

Adena Regional Medical Center

City

Chillicothe

State/Province

Ohio

ZIP/Postal Code

45601

Country

United States

Facility Name

VA Medical Center - Cincinnati

City

Cincinnati

State/Province

Ohio

ZIP/Postal Code

45220

Country

United States

Facility Name

University of Cincinnati Medical Center

City

Cincinnati

State/Province

Ohio

ZIP/Postal Code

45267

Country

United States

Facility Name

Cleveland Clinic Cancer Center - Fairview Hospital

City

Cleveland

State/Province

Ohio

ZIP/Postal Code

44111

Country

United States

Facility Name

Cleveland Clinic Foundation

City

Cleveland

State/Province

Ohio

ZIP/Postal Code

44195

Country

United States

Facility Name

Mount Carmel East Hospital

City

Columbus

State/Province

Ohio

ZIP/Postal Code

43213

Country

United States

Facility Name

Columbus NCI Community Oncology Research Program

City

Columbus

State/Province

Ohio

ZIP/Postal Code

43215

Country

United States

Facility Name

The Mark H. Zangmeister Center

City

Columbus

State/Province

Ohio

ZIP/Postal Code

43219

Country

United States

Facility Name

Mount Carmel Health Center West

City

Columbus

State/Province

Ohio

ZIP/Postal Code

43222

Country

United States

Facility Name

Good Samaritan Hospital and Health Center

City

Dayton

State/Province

Ohio

ZIP/Postal Code

45406

Country

United States

Facility Name

Samaritan North Health Center

City

Dayton

State/Province

Ohio

ZIP/Postal Code

45415

Country

United States

Facility Name

Dayton NCI Community Oncology Research Program

City

Dayton

State/Province

Ohio

ZIP/Postal Code

45420

Country

United States

Facility Name

VA Medical Center - Dayton

City

Dayton

State/Province

Ohio

ZIP/Postal Code

45428

Country

United States

Facility Name

Wayne Hospital

City

Greenville

State/Province

Ohio

ZIP/Postal Code

45331

Country

United States

Facility Name

Cleveland Clinic Cancer Center - Independence

City

Independence

State/Province

Ohio

ZIP/Postal Code

44131

Country

United States

Facility Name

Kettering Medical Center

City

Kettering

State/Province

Ohio

ZIP/Postal Code

45429

Country

United States

Facility Name

Fairfield Medical Center

City

Lancaster

State/Province

Ohio

ZIP/Postal Code

43130

Country

United States

Facility Name

Cleveland Clinic Cancer Center - Mansfield

City

Mansfield

State/Province

Ohio

ZIP/Postal Code

44906

Country

United States

Facility Name

Marietta Memorial Hospital

City

Marietta

State/Province

Ohio

ZIP/Postal Code

45750

Country

United States

Facility Name

Hillcrest Hospital Cancer Center

City

Mayfield Heights

State/Province

Ohio

ZIP/Postal Code

44124

Country

United States

Facility Name

Knox Community Hospital

City

Mount Vernon

State/Province

Ohio

ZIP/Postal Code

43050

Country

United States

Facility Name

Licking Memorial Hospital

City

Newark

State/Province

Ohio

ZIP/Postal Code

43055

Country

United States

Facility Name

Southern Ohio Medical Center

City

Portsmouth

State/Province

Ohio

ZIP/Postal Code

45662

Country

United States

Facility Name

North Coast Cancer Care, Inc.

City

Sandusky

State/Province

Ohio

ZIP/Postal Code

44870

Country

United States

Facility Name

Springfield Regional Medical Center

City

Springfield

State/Province

Ohio

ZIP/Postal Code

45501

Country

United States

Facility Name

Springfield Regional Cancer Center

City

Springfield

State/Province

Ohio

ZIP/Postal Code

45504

Country

United States

Facility Name

Cleveland Clinic Strongsville Family Health Center

City

Strongsville

State/Province

Ohio

ZIP/Postal Code

44136

Country

United States

Facility Name

Upper Valley Medical Centers

City

Troy

State/Province

Ohio

ZIP/Postal Code

45373

Country

United States

Facility Name

South Pointe Hospital

City

Warrensville Heights

State/Province

Ohio

ZIP/Postal Code

44122

Country

United States

Facility Name

St. Ann's Hospital

City

Westerville

State/Province

Ohio

ZIP/Postal Code

43081

Country

United States

Facility Name

Cleveland Clinic Cancer Center - Wooster

City

Wooster

State/Province

Ohio

ZIP/Postal Code

44691

Country

United States

Facility Name

Genesis Healthcare System Cancer Care Center

City

Zanesville

State/Province

Ohio

ZIP/Postal Code

43701

Country

United States

Facility Name

St. Charles Health System

City

Bend

State/Province

Oregon

ZIP/Postal Code

97701

Country

United States

Facility Name

Clackamas Radiation Oncology Center

City

Clackamas

State/Province

Oregon

ZIP/Postal Code

97015

Country

United States

Facility Name

Providence Oncology and Hematology Care Southeast

City

Clackamas

State/Province

Oregon

ZIP/Postal Code

97015

Country

United States

Facility Name

Providence Newberg Medical Center

City

Newberg

State/Province

Oregon

ZIP/Postal Code

97132

Country

United States

Facility Name

Providence Willamette Falls Medical Center

City

Oregon City

State/Province

Oregon

ZIP/Postal Code

97045

Country

United States

Facility Name

Providence Portland Medical Center

City

Portland

State/Province

Oregon

ZIP/Postal Code

97213

Country

United States

Facility Name

Providence St. Vincent Medical Center

City

Portland

State/Province

Oregon

ZIP/Postal Code

97225

Country

United States

Facility Name

McLeod Regional Medical Center

City

Florence

State/Province

South Carolina

ZIP/Postal Code

29501

Country

United States

Facility Name

Gibbs Cancer Center-Gaffney

City

Gaffney

State/Province

South Carolina

ZIP/Postal Code

29341

Country

United States

Facility Name

Gibbs Cancer Center-Pelham

City

Greer

State/Province

South Carolina

ZIP/Postal Code

29651

Country

United States

Facility Name

Spartanburg Medical Cancer

City

Spartanburg

State/Province

South Carolina

ZIP/Postal Code

29303

Country

United States

Facility Name

MGC Hematology Oncology-Union

City

Union

State/Province

South Carolina

ZIP/Postal Code

29379

Country

United States

Facility Name

Wellmont Bristol Regional Medical Center

City

Bristol

State/Province

Tennessee

ZIP/Postal Code

37620

Country

United States

Facility Name

Wellmont Medical Associates Oncology and Hematology

City

Bristol

State/Province

Tennessee

ZIP/Postal Code

37620

Country

United States

Facility Name

Wellmont Medical Assoc Onc and Hem-Johnson City

City

Johnson City

State/Province

Tennessee

ZIP/Postal Code

37604

Country

United States

Facility Name

Holston Valley Hospital and Medical Center

City

Kingsport

State/Province

Tennessee

ZIP/Postal Code

37660

Country

United States

Facility Name

Wellmont Medical Assoc Onc and Hem-Kingsport

City

Kingsport

State/Province

Tennessee

ZIP/Postal Code

37660

Country

United States

Facility Name

Thompson Cancer Survival Center

City

Knoxville

State/Province

Tennessee

ZIP/Postal Code

37916

Country

United States

Facility Name

Don and Sybil Harrington Cancer Center

City

Amarillo

State/Province

Texas

ZIP/Postal Code

79106

Country

United States

Facility Name

University of Utah Medical Center

City

Salt Lake City

State/Province

Utah

ZIP/Postal Code

84132

Country

United States

Facility Name

Southwest Virginia Cancer Center

City

Norton

State/Province

Virginia

ZIP/Postal Code

24273

Country

United States

Facility Name

Island Hospital

City

Anacortes

State/Province

Washington

ZIP/Postal Code

98221

Country

United States

Facility Name

Auburn Regional Medical Center

City

Auburn

State/Province

Washington

ZIP/Postal Code

98001

Country

United States

Facility Name

Virginia Mason Bainbridge Island Medical Center

City

Bainbridge Island

State/Province

Washington

ZIP/Postal Code

98110

Country

United States

Facility Name

Overlake Hospital Medical Center

City

Bellevue

State/Province

Washington

ZIP/Postal Code

98004

Country

United States

Facility Name

Swedish Cancer Inst-Eastside Oncology Hematoly

City

Bellevue

State/Province

Washington

ZIP/Postal Code

98005

Country

United States

Facility Name

PeaceHealth St. Joseph Medical Center

City

Bellingham

State/Province

Washington

ZIP/Postal Code

98225

Country

United States

Facility Name

Swedish Medical Center - Edmonds

City

Edmonds

State/Province

Washington

ZIP/Postal Code

98026

Country

United States

Facility Name

Virginia Mason Federal Way Medical Center

City

Federal Way

State/Province

Washington

ZIP/Postal Code

98002

Country

United States

Facility Name

Tacoma/Valley Radiation Oncology Ctrs-Gig Harbor

City

Gig Harbor

State/Province

Washington

ZIP/Postal Code

98332

Country

United States

Facility Name

MultiCare Gig Harbor Medical Park

City

Gig Harbor

State/Province

Washington

ZIP/Postal Code

98335

Country

United States

Facility Name

Swedish Cancer Institute-Issaquah

City

Issaquah

State/Province

Washington

ZIP/Postal Code

98029

Country

United States

Facility Name

PeaceHealth St. John Medical Center

City

Longview

State/Province

Washington

ZIP/Postal Code

98632

Country

United States

Facility Name

Virginia Mason Lynnwood Medical Center

City

Lynnwood

State/Province

Washington

ZIP/Postal Code

98036

Country

United States

Facility Name

MultiCare Good Samaritan Hospital

City

Puyallup

State/Province

Washington

ZIP/Postal Code

98372

Country

United States

Facility Name

Tacoma/Valley Radiation Oncology Ctrs-Puyallup

City

Puyallup

State/Province

Washington

ZIP/Postal Code

98372

Country

United States

Facility Name

Virginia Mason Medical Center

City

Seattle

State/Province

Washington

ZIP/Postal Code

98101

Country

United States

Facility Name

Minor and James Medical, PLLC

City

Seattle

State/Province

Washington

ZIP/Postal Code

98104

Country

United States

Facility Name

Pacific Cancer Research Consortium NCORP

City

Seattle

State/Province

Washington

ZIP/Postal Code

98104

Country

United States

Facility Name

Pacific Medical Center - First Hill

City

Seattle

State/Province

Washington

ZIP/Postal Code

98104

Country

United States

Facility Name

Swedish Medical Center

City

Seattle

State/Province

Washington

ZIP/Postal Code

98104

Country

United States

Facility Name

Swedish Medical Center - Ballard Campus

City

Seattle

State/Province

Washington

ZIP/Postal Code

98107

Country

United States

Facility Name

Fred Hutchinson Cancer Research Center

City

Seattle

State/Province

Washington

ZIP/Postal Code

98109

Country

United States

Facility Name

Group Health Cooperative-Seattle

City

Seattle

State/Province

Washington

ZIP/Postal Code

98112

Country

United States

Facility Name

Tacoma/Valley Radiation Oncology Ctrs-Jackson Hill

City

Tacoma

State/Province

Washington

ZIP/Postal Code

97405

Country

United States

Facility Name

Mary Bridge Children's Hospital and Health Center

City

Tacoma

State/Province

Washington

ZIP/Postal Code

98405

Country

United States

Facility Name

MultiCare Tacoma General Hospital

City

Tacoma

State/Province

Washington

ZIP/Postal Code

98405

Country

United States

Facility Name

Northwest NCI Community Oncology Research Program

City

Tacoma

State/Province

Washington

ZIP/Postal Code

98405

Country

United States

Facility Name

Tacoma/Valley Radiation Oncology Ctrs-Saint Joe's

City

Tacoma

State/Province

Washington

ZIP/Postal Code

98405

Country

United States

Facility Name

Multicare Health System

City

Tacoma

State/Province

Washington

ZIP/Postal Code

98415

Country

United States

Facility Name

PeaceHealth Southwest Medical Center

City

Vancouver

State/Province

Washington

ZIP/Postal Code

98668

Country

United States

Facility Name

Billings Clinic-Cody

City

Cody

State/Province

Wyoming

ZIP/Postal Code

82414

Country

United States

Facility Name

Welch Cancer Center - Sheridan Memorial Hospital

City

Sheridan

State/Province

Wyoming

ZIP/Postal Code

82801

Country

United States

12. IPD Sharing Statement

Learn more about this trial

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

We'll reach out to this number within 24 hrs

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

Breast Cancer

About this trial

Eligibility Criteria

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

8. Arms, Groups, and Interventions

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial